We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Effects of Reserpine, Iproniazid (Marsilid), and Triiodothyronine (Trionine), and of Reserpine Alone A Comparative Study in One Hundred Seventeen Mentally Ill Patients of Various Diagnostic Categories

AMA Arch Gen Psychiatry. 1959;1(2):215-222. doi:10.1001/archpsyc.1959.03590020111010.
Text Size: A A A
Published online


Tranquilizing drugs in adequate dosage tend to lessen anxiety and tension. They reduce overactivity, hostility, and destructiveness. They may, however, have certain undesirable side-effects, such as excessive weight gain, persistent drowsiness, a reduced capacity for motor functioning, and a reduced capacity for intellectual and emotional release.1,2 They are also ineffective in depressions, suicidal trends, and feeding problems. They may even increase these latter mental symptoms.

We began studies with iproniazid ( Marsilid) and deserpidine, a Rauwolfia alkaloid, in 1955 in chronic schizophrenia.3 Iproniazid is an inhibitor of the brain enzyme which metabolizes serotonin,4 and it decreases the depressant effect of deserpidine or reserpine in schizophrenic patients. It was observed then that a greater weight gain occurred with this drug combination than with either drug alone. Therefore, iproniazid was used alone or with reserpine in depressed feedingproblem patients in our Acute Hospital Di


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.